WO2013004171A1 - 穿心莲内酯c15位取代系列衍生物在制备抗乙型肝炎药物中的应用 - Google Patents
穿心莲内酯c15位取代系列衍生物在制备抗乙型肝炎药物中的应用 Download PDFInfo
- Publication number
- WO2013004171A1 WO2013004171A1 PCT/CN2012/078083 CN2012078083W WO2013004171A1 WO 2013004171 A1 WO2013004171 A1 WO 2013004171A1 CN 2012078083 W CN2012078083 W CN 2012078083W WO 2013004171 A1 WO2013004171 A1 WO 2013004171A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- preparation
- hepatitis
- andrographolide
- bromophenyl
- fluorophenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
- C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Definitions
- the invention relates to the pharmaceutical use of the Hi derivative in Andrographis paniculata, in particular to the application of the andrographolide C15-substituted derivative in the preparation of anti-hepatitis B medicine, belonging to the technical field of medicinal chemistry.
- Andrographolide is a diterpene lactone compound extracted from Andrographis paniculata (Burm. f) Nees. It is one of the main active ingredients of Chinese herbal medicine Andrographis paniculata. It is mainly used in clinical practice. Treatment of upper respiratory tract infections, bacterial dysentery and other diseases. In recent years, the study found that andrographolide also has anti-tumor, liver-protecting and anti-viral effects. There have been many reports on antiviral research on Andrographis paniculata and its extracts.
- Andrographis paniculata extract can effectively treat respiratory tract infections and viral pneumonia, effectively reducing the prevalence and intensity of symptoms associated with common colds; Andrographis paniculata and andrographolide or its derivatives inhibit influenza virus and adenovirus, and herpes
- the virus has a certain delay (CN: 200610080719.6).
- Andrographis paniculata and its derivatives ⁇ anti-flavonoid, prion or hepatitis C virus CN: 200580046253.1>, anti-SARS (CN: 03129127.9).
- the composition of andrographis and other plants or their components have Antiviral effect.
- Hepatitis B virus is a member of the human hepadnaviradae virus family and is the causative agent of hepatitis B. More than 350 million people worldwide are infected with HBV, and about 120 million people in China have long-term hepatitis B virus. Therefore, the market demand for anti-HBV drugs is huge.
- the drugs against the HBV are mainly nucleoside analogs represented by lamivudine and immunomodulators represented by interferons. In clinical applications, there are problems such as rebound, adverse reactions and drug resistance after stopping the drug.
- the andrographolide derivative of the structure of the general formula 1 has a remarkable anti-hepatitis B effect by screening the synthetic compound against hepatitis B activity.
- the purpose of the invention is to provide its use in the preparation of anti-hepatitis B drugs.
- Preferred compounds are: hydrogen; 3 ⁇ 4 is phenyl, 4 fluorophenyl, 4-chlorophenyl, 4 bromophenyl, 3 fluorophenyl, 3 chlorophenyl, 3 bromophenyl or 3-methoxyphenyl , 4-methoxyphenyl; 3 ⁇ 4, is hydrogen.
- the above-mentioned compound proposed by the present invention has been prepared by the invention patent CN: 200510107247.4, and may also be referred to the literature BMC, 2007 (Xu HW, et al.).
- the synthesis method is as follows: dissolving 14-deoxy-1U2-dehydroandrographolide or 14-deoxy-1U2-dehydro-3,19-esterified andrographolide in different aldehydes in methanol or ethanol or In tetrafuran, under the catalysis of the base, the reaction is heated at a temperature of 15 to 7 (TC) to obtain an andrographolide derivative represented by the formula: the base used is sodium carbonate, potassium carbonate, potassium hydrogencarbonate, carbonic acid.
- TC 15 to 7
- the aldehyde used is benzaldehyde, halogenated benzaldehyde, p-methoxybenzaldehyde, etc.
- halogenated benzaldehyde is preferably p-fluorobenzaldehyde, p-chlorobenzaldehyde, p-bromobenzaldehyde
- Esterified andrographolide corresponds to when R 3 , COR 5 , and R 5 are 3 pyridyl groups in Formula 1.
- human hepatoma HepG2.2 15 cells transfected with hepatitis B virus gene were used to study the anti-HBV effect of the andrographolide C 1 5 substituted derivative; the duck hepatitis B virus was used. Infected models to study anti-DHBV effects in vivo. Studies have confirmed that the above compounds have anti-HBVCDHBV) action and can be used for the preparation of anti-HBV drugs.
- the anti-hepatitis B virus is prepared by using the compound as an effective pharmaceutical ingredient or in combination with other drugs according to various conventional pharmaceutical methods and process requirements, and mixing with auxiliary and/or added ingredients acceptable in the pharmaceutical industry. Oral-type preparations, injection-type preparations and the like.
- the oral preparation is a tablet, a pill, a capsule, a granule or a syrup; the injectable preparation includes an injection or a frozen powder dosage form.
- the lamivudine IC 5U is about 10 g/mL (43.67 ⁇ 1/ ⁇ ) ; the drug action time is 9 days;
- ⁇ 2 is the result of the anti-HBV therapeutic index of the derivatives A ⁇ G of the present invention; lamivudine 1! >2; the drug action time is 9d; Figure 3
- the present invention derivatives A ⁇ G (concentration O.35mmol/kg) Anti-DHBV effect in vivo (5d) The results showed that the positive drug lamivudine (3TC) was administered at a dose of 20 mg/kg body weight; compared with the model group, *P ⁇ 0.05 : ** ⁇ 0.01 ⁇
- the results of the anti-DHBV effect of the sputum in the invention are as follows: the positive drug lamivudine (3TC) is 50 mg/kg; compared with the model group, *P ⁇ 0.05, **P ⁇ 0.01appel
- Figure 5 is a graph showing the pathological section of DHBV-infected duck liver tissue by the derivative A of the present invention (HE staining; 400 ⁇ ) ⁇ wherein ⁇ is a normal group, B is a model group, C is a positive drug group, and D is a derivative A of the present invention. In the low dose group, E is the high dose group of the derivative cow A of the present invention.
- the anti-HBV activity is demonstrated by a pharmacological test.
- HepG2.2.15 cells transfected with human hepatitis B virus gene were used to detect the effect of the drug of the present invention on the secretion of HBV surface antigen (HBsAg) from the supernatant of HepG2.2.15 cell culture medium.
- HBV surface antigen HBV surface antigen
- the HepG 2.2.15 cell suspension was inoculated into a 48-well plate with a cell number of 1.25 x]0 4 /?L, plus 0.5 ml of PMI1640 medium, containing 10% fetal bovine serum, 380 g/mL.
- G418, l OC ⁇ g/ m L streptomycin, 100 IU/mL penicillin gas volume fraction 5% C0 2 in a carbon dioxide incubator at 37 ° C, 24 h Change the drug-containing culture solution, and set the drug concentration to 5 gradients.
- Lamivudine (3TC) was used as a positive drug control. The culture solution was changed once in culture for 3 days and 6 days, and the supernatant in the culture well was taken out on the 9th day of culture to perform HBsAg detection. The cells in the plate were assayed for cell viability using the MTT assay.
- the hepatitis B virus surface antigen diagnostic kit (sold product) is used to detect HBsAg according to the instructions.
- a microplate reader BIO-TEK Powerwave X, USA
- a dual-wavelength colorimetric method with a wavelength of 450 nm and a reference wavelength of 630 nm was used to read the OD value of each well. Calculate the inhibition rate and therapeutic index of HBsAg.
- the compounds A to G of the present invention were synthesized by the applicant; lamivudine was commercially available.
- the above test drug was formulated into a 0.5% CMC-Na solution and solubilized with Tween-80 (final concentration 0.1%).
- SYBR Green I is a product of Bao Bioengineering (Dalian) Co., Ltd.
- the upper and lower bows are synthesized by oyster bioengineering (Shanghai) Co., Ltd.
- One day old cherry valley ducks were aseptically collected from the jugular vein by about 200 ⁇ , serum was separated, DNA was extracted, and ducklings with congenital DHBV negative and uniform body condition were screened by ordinary PCR method for experimental use.
- Three-day-old negative ducks were challenged with DHBV-positive duck serum (200 ⁇ /only) via the leg and sputum. Seven days after infection, blood was collected from the cervical vein, and the serum was separated.
- Animals were given intragastrically every morning according to the weight of the stomach, 1 time / day, lmL / 200g; first select a representative compound for primary screening, 5 days of administration, aseptic operation, blood collection from the jugular vein, separation of serum, analysis DHBV-DNA copy number in serum, and the inhibition rate was calculated. Further, the compound A with better activity was selected for 2 weeks (once/day), and the jugular vein was collected at 7d, 14d and 5d after the administration, and the serum was separated to analyze the DHBV-D_N A copy number in the serum. , calculate the inhibition rate.
- DHBV-DNA inhibition rate (%) (model groupcopies-administration group copies) / model groupcopiesx l00%
- Experimental data were processed by SPSS 17.0 statistical software, and statistical analysis was performed by t-gun test. Data are expressed as mean ⁇ standard deviation ( X ⁇ S ), to ? ⁇ 0.05 as a significant statistically significant difference.
- the test compound could significantly reduce the copy number of DHBV DNA in serum, which was P ⁇ 0.05 compared with the model group, and the inhibition rate of compound A was 57.8%, compared with the model group. ⁇ 0.01. It is indicated that the compound of the present invention has a clear anti-DHBV effect in vivo.
- the progression of the DHBV-DNA in serum was studied in the step-by-step with compound A as the representative of the drug for 7 days, 14 days and 5 days after drug withdrawal. The results showed that compared with the model group, the low and high dose groups of Compound A significantly reduced the DHB DNA copy number in serum, and the anti-DHBV effect of Compound A remained almost unchanged 5 days after drug withdrawal.
- Drugs Compounds A to G of the present invention.
- mice showed no obvious scorpion venom and no death, indicating that the acute toxicity of the compounds was minimal.
- the derivatives have clear anti-HBV, liver-protecting activity, high efficiency and low toxicity, and can be used to treat and prevent the preparation of hepatitis B drugs, and provide possibilities for the development and screening of clinical drugs. Has application value.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/130,695 US20140187627A1 (en) | 2011-07-04 | 2012-07-03 | Uses of c15-substituted andrographolide derivatives in the preparation of anti-hepatitis b virus medicament |
JP2014517429A JP5923167B2 (ja) | 2011-07-04 | 2012-07-03 | 抗b型肝炎薬の調製のためのアンドログラホリドc15位置換シリーズ誘導体の使用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011101842944A CN102302487B (zh) | 2011-07-04 | 2011-07-04 | 穿心莲内酯c15位取代系列衍生物在制备抗乙型肝炎药物中的应用 |
CN201110184294.4 | 2011-07-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013004171A1 true WO2013004171A1 (zh) | 2013-01-10 |
Family
ID=45376477
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2012/078083 WO2013004171A1 (zh) | 2011-07-04 | 2012-07-03 | 穿心莲内酯c15位取代系列衍生物在制备抗乙型肝炎药物中的应用 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20140187627A1 (zh) |
JP (1) | JP5923167B2 (zh) |
CN (1) | CN102302487B (zh) |
WO (1) | WO2013004171A1 (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102302487B (zh) * | 2011-07-04 | 2013-04-10 | 郑州大学 | 穿心莲内酯c15位取代系列衍生物在制备抗乙型肝炎药物中的应用 |
CN102526026B (zh) * | 2012-02-10 | 2013-07-03 | 郑州大学 | 15-苄亚基-14-脱氧-11,12-脱氢穿心莲内酯衍生物在制备保肝药物中的用途 |
CN102600129B (zh) * | 2012-02-10 | 2014-05-28 | 郑州大学 | 穿心莲内酯c15位取代衍生物在制备抗丙型肝炎药物中的应用 |
WO2013117149A1 (zh) * | 2012-02-10 | 2013-08-15 | 郑州大学 | 15-苄亚基-14-脱氧-11,12-脱氢穿心莲内酯衍生物在制备保肝及抗丙肝病毒药物中的用途 |
CN103739597B (zh) * | 2014-01-09 | 2016-04-06 | 中国科学院昆明植物研究所 | 14-脱氧-14,15-二脱氢穿心莲内酯衍生物及其药物组合物和用途 |
WO2018177301A1 (zh) * | 2017-04-01 | 2018-10-04 | 郑州大学 | 15-亚基-14-脱氧-11,12-脱氢穿心莲内酯衍生物及其在制备抗纤维化药物中的应用 |
CN109796429B (zh) * | 2018-03-02 | 2023-04-11 | 郑州大学 | 穿心莲内酯十氢萘结构修饰衍生物系列iii及其制备方法和用途 |
US20220047663A1 (en) * | 2020-08-12 | 2022-02-17 | Shibban Krishen Ganju | Formulation for inhibiting virus replication |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101416958A (zh) * | 2008-12-15 | 2009-04-29 | 郑州大学 | 15-亚甲基取代穿心莲内酯衍生物在制备抗乙型肝炎药物中的用途 |
CN102302487A (zh) * | 2011-07-04 | 2012-01-04 | 郑州大学 | 穿心莲内酯c15位取代系列衍生物在制备抗乙型肝炎药物中的应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100543021C (zh) * | 2005-12-07 | 2009-09-23 | 郑州大学 | 穿心莲内酯c15位取代系列衍生物及其制备方法 |
CN101416959B (zh) * | 2008-12-15 | 2010-11-10 | 郑州大学 | 15-亚甲基取代穿心莲内酯衍生物在制备抗炎解热镇痛药物中的用途 |
CN101972247B (zh) * | 2010-10-22 | 2012-06-06 | 郑州大学 | 15-苄亚基-14-脱氧-11,12-脱氢穿心莲内酯衍生物的药物用途 |
-
2011
- 2011-07-04 CN CN2011101842944A patent/CN102302487B/zh active Active
-
2012
- 2012-07-03 JP JP2014517429A patent/JP5923167B2/ja active Active
- 2012-07-03 WO PCT/CN2012/078083 patent/WO2013004171A1/zh active Application Filing
- 2012-07-03 US US14/130,695 patent/US20140187627A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101416958A (zh) * | 2008-12-15 | 2009-04-29 | 郑州大学 | 15-亚甲基取代穿心莲内酯衍生物在制备抗乙型肝炎药物中的用途 |
CN102302487A (zh) * | 2011-07-04 | 2012-01-04 | 郑州大学 | 穿心莲内酯c15位取代系列衍生物在制备抗乙型肝炎药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
JP5923167B2 (ja) | 2016-05-24 |
CN102302487B (zh) | 2013-04-10 |
CN102302487A (zh) | 2012-01-04 |
US20140187627A1 (en) | 2014-07-03 |
JP2014518225A (ja) | 2014-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2013004171A1 (zh) | 穿心莲内酯c15位取代系列衍生物在制备抗乙型肝炎药物中的应用 | |
Bailly et al. | Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome? | |
TWI298259B (en) | Pharmaceutical composition for inhibiting/treating brain cancer | |
Wu et al. | In vivo and in vitro antiviral activity of hyperoside extracted from Abelmoschus manihot (L) medik | |
WO2007012254A1 (fr) | Conjugues de rhein, leur procede de preparation et leurs utilisations pour preparer des medicaments permettant de traiter la nephropathie diabetique, les adherences intestinales et l'osteoarthrite | |
WO2005087242A1 (en) | Traditional chinese medicine preparation for cardio-cerebral blood vessel diseases and its preparing method | |
US20200268770A1 (en) | Pharmaceutical composition used for treating metabolic syndrome disorders, infectious diseases, and complications thereof | |
KR20160070152A (ko) | 혈구 감소를 예방 또는 치료하기 위한 약물의 제조에 있어서의 이카리틴의 용도 | |
CN101214285B (zh) | 虎杖提取物用于制备抗艾滋病毒和抗乙肝病毒产品的用途 | |
Zhu et al. | Anti-hepatitis B virus activity of lithospermic acid, a polyphenol from Salvia miltiorrhiza, in vitro and in vivo by autophagy regulation | |
CN103880856B (zh) | 没药烷型倍半萜类衍生物及其药物组合物和其在制药中的应用 | |
CN103096885B (zh) | 不饱和脂肪酸用于抑制病毒复制和/或感染的用途 | |
KR101665015B1 (ko) | 복합 생약 추출물을 유효성분으로 함유하는 항바이러스용 조성물 | |
CN114699436A (zh) | 一种防治流感的中药提取物组合物及其制备方法和应用 | |
CN103784427A (zh) | 含桉烷型倍半萜的药物组合物及其在制药中的应用 | |
CN106822152B (zh) | 一种药物组合物及其应用 | |
CN102050780B (zh) | 喹啉衍生物,其药物组合物及其用途 | |
CN110201068B (zh) | 一种克感利咽组合物或制剂在制备防治登革热病药物中的应用 | |
JP6013516B2 (ja) | 15−ベンジリデン−14−デオキシ−11,12−ジデヒドロアンドログラホリド誘導体の肝臓保護及び抗c型肝炎ウイルス医薬品製造における使用 | |
RU2662161C1 (ru) | Ингибитор входа вируса гепатита и фармацевтическая композиция для лечения гепатита | |
CN102370983B (zh) | 一种抗肿瘤药物组合物及其用途 | |
CN107281177B (zh) | 促进造血干细胞归巢和植入的方法 | |
KR101665016B1 (ko) | 복합 생약 추출물을 유효성분으로 함유하는 항바이러스용 조성물 | |
CN111084808A (zh) | 咳特灵制剂在治疗乙型肝炎中的应用 | |
JP2005500995A (ja) | B型肝炎ウイルスにより起きる感染症の治療または予防のためのフィランタス属構成部分の使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12807349 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2014517429 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14130695 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12807349 Country of ref document: EP Kind code of ref document: A1 |